{"nctId":"NCT00292461","briefTitle":"A Study for Evaluating the Efficacy and Safety of Zonisamide and Lamotrigine (Lamictal) for Subjects With Refractory Simple Partial, Complex Partial or Partial With Secondary Generalized Seizures","startDateStruct":{"date":"2006-03"},"conditions":["Epilepsy"],"count":64,"armGroups":[{"label":"zonisamide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Zonisamide"]},{"label":"lamotrigine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lamotrigine"]}],"interventions":[{"name":"Zonisamide","otherNames":[]},{"name":"Lamotrigine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Subjects must sign and date the informed consent form\n* Clinical diagnosis as refractory epilepsy\n\nExclusion criteria:\n\n* Progressive neurologic disease\n* Serious psychiatric disease\n* Hemolytic anemia\n* G6PD (glucose-6-phosphate dehydrogenase) deficiency\n* Acute intermittent porphyrias\n* Subjects who have received study drugs (Zonisamide, Lamotrigine) in the past\n* Drug or alcohol addiction\n* Renal impairment (serum creatinine â‰§ 1.5 mg/dl), or hepatic abnormality (ALT or AST \\> 2x ULN)\n* Stevens-Johnson syndrome\n* Progressive exfoliative dermatitis\n* Pregnant, lactating or of childbearing potential female\n* Regularly taking oral contraceptives\n* Hypersensitivity to study drugs\n* Severe cardiac disease (New York Heart Association Functional Class III and IV)\n* History of malignancy within 5 years\n\n  * Taking valproic acid within 7 days prior to screening\n  * Subjects with simple partial seizures without motor component","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage Change of Monthly Seizure Frequency at the End of the 16-week Treatment From Baseline","description":"Percentage Change of Frequency = (T-B)/B\\*100% T= Total seizure frequency during maintenance dose period / maintenance dose period (weeks)\\* 4 B= The monthly seizure frequence with one month prior to enrollment","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.7","spread":null},{"groupId":"OG001","value":"-35.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Assessment of Efficacy by Physician at the End of 16-week Treatment Period","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Global Assessment of Efficacy by Participants at the End of the 16-week Treatment Period","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Response Rate: Defined as the Percentage of Participants With >= 50% Reduction of Monthly Seizure Frequency at the End of 16-week Treatment From Baseline.","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45.8","spread":null},{"groupId":"OG001","value":"45.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":34},"commonTop":["dizziness","somnolence","Hepatic enzyme abnormal","rash","diplopia"]}}}